How should modern analytical development be conducted?
Recommendation

Tuesday, 10 November 2026 9 .00 - 17.00 h
In 2017, the board of the ECA Foundation's Analytical Quality Control Group (AQCG) has decided to strengthen the lifecycle approach for analytical procedures. Therefore, the Group developed a new guideline on "Analytical Procedure Lifecycle Management".
The draft for this guideline was discussed with the participants of the Analytical Procedure Lifecycle Management Conference on 23/24 November, 2017 in Vienna. The conference objective was to collect proposals and suggestions for the final version of this guideline. Meanwhile, the ECA QC Group has considered the received suggestions and implemented them as far as possible.
The AQCG is currently in the process of finalizing the final Version 1.0.
In this comprehensive Analytical Procedure Lifecycle Management guideline, the following points are presented and discussed:
- Key References
- Quality involvement/Responsibilities
- Rationale for this Guideline
- Principles of Analytical Procedure Lifecycle Management (APLM)
- Prerequisites for the APLM
- Guidance recommendations for the 3 stages of the APLM
- Stage 1: Procedure Design and Development
- Procedure development and gaining understanding
- Establishing an Analytical Control Strategy
- Establishing a Replication Strategy
- Stage 2: Procedure Performance Qualification
- Stage 3: Procedure Performance Verification
- Technical Glossary
The final Version 1.0 of this guideline will be presented at the ECA APLM Workshop on 20 November 2018 as part of the PharmaLab Congress 2018 in Düsseldorf/Neuss in Germany. Each participant will receive a copy of this important new APLM document, and thereby an important tool for implementing a lifecycle approach to analytical development in one's own company.
Related GMP News
02.11.2026FDA Warning Letter: When Test Procedures Allow Retesting Until an Acceptable Result is Obtained
21.10.2026EMA Updates Information Page on Bioequivalence Guidelines
21.10.2026BP Publishes new Draft Texts
21.10.2026FDA Identifies Critical Deficiencies in Analytical Testing and CGMP Oversight
07.10.2026Analytical Quality Group Developments May through August 2026
07.10.2026Two New FDA Warning Letters Put OOS Investigations in Focus


